scholarly journals Cervical Cytology–Histology Correlation Based on the American Society of Cytopathology Guideline (2017) at the Russian National Medical Research Center for Obstetrics, Gynecology, and Perinatology

Diagnostics ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 210
Author(s):  
Aleksandra Asaturova ◽  
Darya Dobrovolskaya ◽  
Alina Magnaeva ◽  
Anna Tregubova ◽  
Guldana Bayramova ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Medical Research ◽  
Sampling Error ◽  
Pap Test ◽  
Research Center ◽  
National Medical ◽  
American Society ◽  
Screening Errors ◽  
Discrepancy Detection ◽  
Self Learning

Recent evidence suggests that a cytology–histology correlation (CHC) with discrepancy detection can both evaluate errors and improve the sensitivity and specificity of the cytologic method. We aimed to analyze the errors in cytologic–histologic discrepancies according to the CHC protocol guideline of the American Society of Cytopathology (2017). This retrospective study included 273 patients seen at the National Medical Research Center of Obstetrics, Gynecology and Perinatology (Moscow, Russia) between January 2019 and September 2021. The patients’ mean age was 34 ± 8.1 years. The cytology–histology agreement was noted in 158 cases (57.9%). Major discrepancies were found in 21 cases (7.6%), while minor discrepancies were noted in 93 cases (34.1%). The reason for 13 (4.8%) discrepancies was a colposcopy sampling error and, in 46 (16.8%) cases, the reason was a Papanicolaou (PAP) test sampling error. The discrepancy between primary and reviewed cytology was due interpretive errors in 13 (4.8%) cases and screening errors in 42 (15.4%) cases. We demonstrated that the ASC guidelines facilitate cervical CHC. A uniform application of these guidelines would standardize cervical CHCs internationally, provide a scope for the inter-laboratory comparison of data, and enhance self-learning and peer learning.

IPILIMUMAB IN PATIENTS WITH DISSEMINATED MELANOMA: THE N.N. PETROV NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY EXPANDED ACCESS PROGRAM EXPERIENCE

2018 ◽  
Vol 64 (3) ◽  
pp. 388-393
Author(s):  
Yekaterina Anokhina ◽  
V. Rubinchik ◽  
Yekaterina Yaremenko ◽  
Gulfiya Teletaeva ◽  
Dilorom Latipova ◽  
...  
Keyword(s):  
Overall Survival ◽  
Adverse Events ◽  
Medical Research ◽  
Research Center ◽  
Expanded Access ◽  
Risk Of Death ◽  
National Medical ◽  
Expanded Access Program ◽  
Access Program

Ipilimumab (IPI) provides a ten-year overall survival in almost 20 % of selected patients participated in several phase II-III trials. However, the expanded access program (EAP) looks more like routine practice than like clinical trials& This is why the results of such application could be different. Here we present the long-term follow-up data of single center EAP. Ninety-six patients with disseminated melanoma progressing after at least one lines of drug therapy were included at the N.N. Petrov National Medical Research Center of Oncology. Sixty-seven (70 %) patients had stage IV M1c, 35 patients (36 %) had elevated LDH before initiating IPI therapy. All patients received IPI 3 mg / kg IV every 3 weeks for a maximum of 4 cycles. Totally, 320 cycles (mean - 3.3 per patient) were conducted. Grade 3-4 immuno-mediated adverse events (imAE) observed in 18 (19 %) patients. Three patients died of adverse events, possibly associated with ongoing therapy. The median time to progression was 3 (95 % CI, 2.4 to 3.5) mo., the median overall survival was 13 (95 % CI, 8.3 to17.6) mo. Previous immunotherapy with dendritic cell vaccines decreased the risk of death by 48 % (Log-rank p = 0.049). The wild type BRAF status increased three-year overall survival from 29 to 68 % (p = 0.042). Our data confirms long-term safety and efficacy of IPI in patients with pretreated disseminated melanoma in the close to real practice setting.

scholarly journals Pharmacokinetics of 13-cis-Retinoic acid in high-risk neuroblastoma patients

2020 ◽  
Vol 19 (4) ◽  
pp. 20-31
Author(s):  
E. A. Litvin ◽  
D. T. Utalieva ◽  
D. Yu. Kachanov ◽  
A. V. Pshonkin ◽  
M. Ya. Yadgarov ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
High Risk ◽  
Medical Research ◽  
High Performance ◽  
Plasma Concentrations ◽  
Neuroblastoma Cells ◽  
Research Center ◽  
Therapeutic Drug ◽  
Pediatric Hematology ◽  
National Medical

13-cis-Retinoic acid is a differentiation agent for neuroblastoma cells and is a part of post-consolidation therapy for high-risk patients. The effectiveness of this therapeutic approach is currently under study. 26 patients with high-risk neuroblastoma treated at Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology were included in the study of 13-cis-Retinoic acid pharmacokinetics by high-performance liquid chromatography assay with ultraviolet detector depending on the method of administration of drug (swallowed capsules or opened capsules before administration). This study is supported by the Independent Ethics Committee and approved by the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The current study showed that the therapeutic concentration of > 2 μM when taking 13-cis-Retinoic acid at a dose of 160 mg/m2/day was achieved in two groups, regardless of the method of drug administration. However, plasma concentrations of 13-cis-Retinoic acid at 4 hours after administration on the 14th day of therapy were higher in the group of patients who swallowed the capsules (4.1 ± 1.8 μM), compared to those who could not do it (1.9 ± 1.5 μM) (p = 0.022). The introduction into the clinical practice of therapeutic drug monitoring of 13-cis-retinoic acid in high-risk neuroblastoma patients with an assessment of peak concentration and dose adjustment of the following courses may be an important point in the attempt to optimize postconsolidation therapy and improve prognosis.

scholarly journals Non-spherocytic hemolytic anemia caused by erythrocyte pyruvate kinase defiiency: the analysis of genetic defects in pediatric patients, living in Russian Federation

2021 ◽  
Vol 20 (2) ◽  
pp. 84-96
Author(s):  
E. A. Cherniak ◽  
N. E. Sokolova ◽  
K. V. Semiglazova ◽  
I. N. Lavrentyeva ◽  
E. K. Donush ◽  
...  
Keyword(s):  
Medical Research ◽  
Hemolytic Anemia ◽  
Research Center ◽  
Compound Heterozygous ◽  
Missense Mutations ◽  
Pediatric Hematology ◽  
Transfusion Independence ◽  
National Medical ◽  
Retrospective Data Analysis ◽  
Minimum Age

The article presents retrospective data analysis of a cohort of patients with PKD (n = 41 patients, aged 4 months – 26,5 years, median of age – 5 years 1 month) who were examined at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology for unspecifid hereditary hemolytic anemia during the period 2013–2020. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. In all patients, the diagnosis was confimed by Next Generation sequencing (NGS). The homozygous mutations in the PKLR gene were found in 10 patients (24.39%), compound heterozygous mutations in 31 patients (75.61%), 77.78% of them were missense mutations. Gender distribution (male:female) was 1:1.73. At least once transfusion of erythrocyte suspension was required to 40 (97.56%) patients. The minimum age at the time of the debut of transfusion dependence was the fist day of life, the maximum was 4 years. Exchange blood transfusion was performed in 13 children, severe normocytic hyperregenerative anemia with transfusion of red blood cells in the fist days of life was noted in 12 children, at the 1st month of life – in 9 children, at the 2nd month of life – in 8 children, at the 3rd month – in 6 children, at the 5th month – in 2 children, at the 1st year – in 1 child, and 2 children underwent single transfusions on the background of infectious episodes at 3 and 4 years respectively. Splenectomy due to high transfusion dependence was performed in 10 patients: transfusion independence was achieved in 5 patients, in 5 – an increase in the interval between blood transfusions. Median of surgical intervention (9 patients): 7 years 4 months, minimum age – 1 year 4 months, maximum – 14 years 4 months. In total, 36 genotypes were described in 41 patients, among them were: c.1529G>A in 3 patients, c.1137_1139del / c.1456C>T – in 2 patients, c.1079G>A/c.1529G>A in 2 patients, c.1130T>C/c.1456C>T in 2 patients, other genotypes occurred once. Two mutations were the most frequent: c.1456C>T (16.67%) and c.1529G>A (16.67%). 19 (46,34%) of patients had previously not described mutations.

History of the Medical and Rehabilitation Clinical Center “Yudino” — Branch of the National Medical Research Center of Rehabilitation and Balneology (1988–2021)

2021 ◽  
pp. 18-24
Author(s):  
M. A. Eremushkin
Keyword(s):  
Medical Research ◽  
Research Center ◽  
National Medical ◽  
Clinical Center ◽  
History Of

В работе рассмотрены вопросы создания и деятельности лечебно-реабилитационного клинического центра «Юдино» — филиала Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр реабилитации и курортологии» Министерства здравоохранения Российской Федерации с начала его открытия (1988 г.) по текущее время, с указанием его бывших и настоящего руководителей, отмечены основные достижения и наработки, полученные в реабилитационном комплексе в прошлом и современные направления его деятельности

History of the Medical and Rehabilitation Clinical Center “Yudino” — Branch of the National Medical Research Center of Rehabilitation and Balneology (1988–2021)

2021 ◽  
pp. 8-14
Author(s):  
M. A. Eremushkin
Keyword(s):  
Medical Research ◽  
Research Center ◽  
National Medical ◽  
Clinical Center ◽  
History Of

В работе рассмотрены вопросы создания и деятельности лечебно-реабилитационного клинического центра «Юдино» — филиала Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр реабилитации и курортологии» Министерства здравоохранения Российской Федерации с начала его открытия (1988 г.) по текущее время, с указанием его бывших и настоящего руководителей, отмечены основные достижения и наработки, полученные в реабилитационном комплексе в прошлом и современные направления его деятельности.

The Professional Retraining Program in Radiotherapy for Medical Physicists

2018 ◽  
pp. 68-73
Author(s):  
А. Черняев ◽  
A. Chernyaev ◽  
П. Борщеговская ◽  
P. Borschegovskaya ◽  
С. Варзарь ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Ionizing Radiation ◽  
Medical Research ◽  
Radiation Safety ◽  
Research Center ◽  
State University ◽  
National Medical ◽  
Medical Physicists ◽  
Radiation Medicine ◽  
Moscow State University

The article assesses the personnel situation in the field of domestic radiation therapy and nuclear medicine. Despite the fact that in recent years there has been a significant re-equipping of Russian medical centers with the latest devices, the quantitative indicators of medical equipment normalized for the number of residents of the country are still significantly inferior to the indexes other countries. And this problem is greatly aggravated by the insufficient number of specialists who can work on the equipment supplied. First and foremost, this refer to medical physicists who are responsible not only for ensuring the required accuracy when applying a dose of ionizing radiation to the tumor, but also for ensuring radiation safety when working with sources of ionizing radiation. A continuing vocational educational retraining program covering development, operation and application of high-tech systems for radiotherapy is being proposed. This program was developed and tested at the Department of Physics of Accelerators and Radiation Medicine of the Physical Faculty of M.V. Lomonosov Moscow State University with the support of the Rusnano Foundation for Educational Programs. The co-executors in the development and approbation of the Program were the National Medical Research Center of Radiology, A.I. Burnasyan Federal Medical Biophysical Center of the FMBA of Russia. Invited experts in the process of developing the Program were scientists and specialists of the Bauman MSTU, Tomsk Polytechnic University, NRNU MEPhI, N.N. Blokhin National Medical Research Center of Oncology. As a result of a professional educational program, the necessary professional skills for working as specialists in radiotherapy units and nuclear medicine centers are formed, which will successfully solve the problem of professional human resources for the clinical centers of Russia. The program was developed and successfully implemented at the Department of Physics of Accelerators and Radiation Medicine of the Physics Department of M.V. Lomonosov Moscow State University. The need to develop a program of assessment of medical physicists, which are working at the moment, is being considered. This will guarantee a high level of knowledge necessary for full participation in the medical process and making responsible decisions on the therapeutic use of radiation devices and ensuring radiation safety of patients and personnel.

scholarly journals Therapy intensification in high-risk neuroblastoma patients with poor response to standard induction: experience of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology

2019 ◽  
Vol 18 (4) ◽  
pp. 19-28
Author(s):  
T. V. Shamanskaya ◽  
D. Y. Kachanov ◽  
A. V. Dumacheva ◽  
M. V. Teleshova ◽  
D. V. Shevtcov ◽  
...  
Keyword(s):  
High Risk ◽  
Medical Research ◽  
Induction Therapy ◽  
Poor Response ◽  
Research Center ◽  
Long Term Results ◽  
Type I ◽  
Pediatric Hematology ◽  
National Medical

High-risk neuroblastoma (NB) is characterized by unsatisfactory treatment results and low probability of long-term survival despite the multimodal therapeutic approach (chemotherapy, surgical treatment, radiation therapy, autologous hematopoietic stem cell transplantation, etc.). One of the prognostic factors in this cohort of patients is the response to induction therapy. The article presents the experience of the intensification of induction therapy in 12 patients with high-risk NB with a poor response (mixed response, stable disease) to standard induction therapy who received treatment at Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, assessing its impact on the prognosis of the disease. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Patients received an additional two courses of chemotherapy with the inclusion of a type I topoisomerase inhibitor topotecan (TCE – topotecan, cyclophosphamide, etoposide). This regimen of intensification of therapy has demonstrated its feasibility. The main grade 3–4 toxicity was hematologic. An improvement in response was achieved in 5/12 (41.6%) patients. However, long-term results of therapy remained unsatisfactory. The 3-year EFS was 16.7% (95% CI 0.0–37.8), the 3-year OS was 50.0% (95% CI 21.7–78.3). Thus, the intensification of therapy in patients with high-risk NB with a poor response to standard induction therapy did not improve treatment outcomes.

Sign in / Sign up

Export Citation Format

Share Document